North America Uterine Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 7,946.03 |
 CAGR |
% |
| Major Markets Players |
北美子宫癌诊断市场，按诊断类型（基于仪器和基于程序）、类型（子宫内膜癌和子宫肉瘤）、年龄组（60）、最终用户（医院、诊断中心、癌症研究中心、门诊手术中心、专科诊所等）、分销渠道（直接招标、第三方分销商等）划分 - 行业趋势和预测到 2030 年。
北美子宫癌诊断市场分析与洞察
子宫癌是女性生殖系统中最常见的癌症。它是一种恶性肿瘤，始于子宫细胞，可扩散至身体其他部位。根据美国癌症协会 (ACS) 的研究，子宫肉瘤占全球所有子宫癌的 5%，而子宫内膜癌是最常见的子宫癌形式。
Data Bridge Market Research 分析，北美子宫癌诊断市场预计到 2030 年将达到 79.4603 亿美元，预测期内复合年增长率为 11.2%。由于女性人口肥胖率上升和北美子宫癌患者增加，诊断类型占市场最大份额。本市场报告还深入介绍了定价分析、专利分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制至 2020-2015) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按诊断类型（基于仪器和基于程序）、类型（子宫内膜癌和子宫肉瘤）、年龄组（<30、31-40、41-50、51-60 和 >60）、最终用户（医院、诊断中心、癌症研究中心、门诊手术中心、专科诊所等）、分销渠道（直接招标、第三方分销商等） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
F-Hoffmann La Roche Ltd.、Siemens Healthcare Private Limited、Narang Medical Limited、ESAOTE SPA、Olympus Corporation、Arquer Diagnostics Ltd、Guzip Biomarkers Corporation、通用电气、Canon Medical Systems ANZ Pty Limited.、KARL STORZ、美敦力、史赛克、Surtex Instruments Limited.、荷兰皇家飞利浦电子公司、富士胶片公司、AED、Jalal Surgical、Integra LifeSciences、B. Braun Melsungen AG 和 GRAIL 等 |
北美子宫癌诊断市场定义
子宫癌的诊断包括超声检查、活检程序和血液检查。超声检查使用声波并产生卵巢和子宫的图像。子宫癌的诊断测试包括两种类型的超声检查：腹部超声检查和经阴道超声检查。腹部扫描检查包括用小探针扫描腹部的全膀胱，而经阴道扫描包括将探针管插入阴道进行扫描或创建图像。活检程序包括子宫内膜活检、宫腔镜检查和扩张和刮除术。
癌症是全球主要死亡原因之一，这种疾病的发病率以惊人的速度增长。因此，卫生专业人员正致力于开发有效的筛查和治疗方案，以控制肥胖率。此外，子宫内膜活检包括从子宫内膜切除一些恶性组织并将其送去进行检测。美国老年女性数量的增加也是子宫癌诊断市场增长的主要因素。
北美子宫癌诊断市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 子宫癌诊断的技术进步
子宫癌是一种常见的妇科疾病，可通过多种检查进行诊断，包括盆腔检查、子宫内膜活检、刮宫术 (D&C)、经阴道超声、计算机断层扫描 (CT 或 CAT)、磁共振成像 (MRI) 和肿瘤生物标志物检测。传统的癌症检测和监测方法主要依赖于成像，并在可能的情况下依赖于血液中的蛋白质生物标志物，其中许多生物标志物是非特异性的。大多数子宫癌病例都是在晚期才被诊断出来的，因为其症状通常不具特异性。子宫癌的体征和症状因人而异，因此很难提供准确的早期诊断。这需要个性化的诊断计划，其中包括多项诊断测试。
因此，子宫癌诊断技术的进步有望推动市场的增长。
- 对微创先进筛查技术的需求不断增长
子宫癌，尤其是子宫内膜癌，是人类发展指数极高地区女性中第五大常见癌症（按年龄标准化比率计算），其发病率在过去几年中有所上升。诊断子宫内膜癌的标准方法包括门诊盆腔超声检查以及子宫内膜增厚情况下的子宫内膜乳头取样。诊断不明确时建议进行宫腔镜检查。局限性包括插入不成功（有时由于宫颈狭窄或脱垂）导致的样本不足以及子宫内膜超声表现异常。因此，所谓的子宫癌标准诊断方法存在一些局限性。
因此，对微创先进筛查技术的需求不断增长预计将推动市场的增长。
克制
- 诊断测试期间的高风险并发症
有几种筛查测试可用于检测子宫癌，其中包括 PAP 测试、经阴道超声和子宫内膜取样（活检）等。虽然这些测试被认为是诊断子宫癌的标准方法，但它们也有相关风险，包括假阴性和假阳性结果以及出血、不适、感染和子宫穿刺等副作用。
如上所述，目前的子宫癌诊断和筛查测试存在许多并发症，使患者面临进一步的风险。这些风险预计将抑制北美子宫癌诊断市场的增长。
机会
- 子宫癌发病率不断上升
子宫癌是最常见的妇科癌症类型。超过 90% 的子宫癌始于子宫内膜，即子宫内膜组织。随着患病率的上升，有前景的新疗法和治疗性生物制剂的推出以及激素抗癌药物因副作用较少而快速增长也在增加。患者和医疗保健提供者对子宫癌发病率的认识正在提高，他们现在更积极地了解这些疾病的诊断和治疗方法，这有望成为市场增长的机会。
2010 年至 2019 年，子宫癌新发病例率每年上升 0.6%，死亡率同期平均每年上升 1.7%。随着子宫癌患者率的增加，用于癌症诊断的治疗方法和先进技术的使用将会增加，这是一个市场增长的机会。
挑战
- 缺乏诊断基础设施
子宫癌等非传染性疾病和其他类型的癌症现在已被联合国和世卫组织确认为重大公共卫生危机。癌症是这一问题的最大部分，卫生系统面临着改善癌症治疗、控制成本和提高系统效率的重大挑战。高收入国家与中低收入国家在治疗方法和结果方面的差异是惊人的。造成这种差异的原因包括成本、获得治疗的机会、劳动力和培训差距以及外行和医务界缺乏认识。诊断和治疗在这种复杂的环境中发挥着重要作用。世界不同地区和国家拥有不同的卫生系统，但其中大多数是分散的或协调不力的。迫切需要扩大中低收入国家的癌症治疗。
新冠肺炎疫情对北美子宫癌诊断市场的影响
新冠肺炎疫情导致与子宫筛查、癌前护理和异常筛查结果管理相关的选择性医疗服务中断。这可能导致子宫癌发病率上升，加剧现有的健康不平等。
制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作，以改善北美子宫癌诊断市场的技术和检测结果。
最新动态
- 2022 年 11 月，荷兰皇家飞利浦公司在北美放射学会 (RSNA) 年会上宣布在北美推出下一代紧凑型便携式超声解决方案，旨在为更多患者带来与高级推车式超声系统相关的诊断质量。它便携且用途广泛，具有良好的图像质量或性能。它与飞利浦超声系统 Affiniti 和 EPIQ 换能器兼容。这有助于该公司扩大其产品组合
- 2022 年 4 月，美敦力和 GE Healthcare 宣布合作，重点关注门诊手术中心 (ASC) 和办公室实验室 (OBL) 的独特护理需求。通过此次合作，客户可以获得广泛的产品组合、财务解决方案和卓越的服务。GE Healthcare 介入影像解决方案旨在帮助我们的客户为患者提供更高水平的护理，这对癌症患者非常有用。这有助于公司扩大业务
北美子宫癌诊断市场范围
北美子宫癌诊断市场细分为诊断类型、类型、年龄组、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按诊断类型
- 基于仪器
- 基于程序
根据诊断类型，北美子宫癌诊断市场分为基于仪器的和基于程序的。
按类型
- 子宫内膜癌
- 子宫肉瘤
根据类型，北美子宫癌诊断市场分为子宫内膜癌和子宫肉瘤。
按年龄组
- <30年
- 31-40岁
- 41-50岁
- 51-60岁
- >60岁
根据年龄组，北美子宫癌诊断市场细分为 <30、31-40、41-50、51-60 和 >60。
由最终用户
- 医院
- 诊断中心
- 癌症研究中心
- 门诊手术中心
- 专科诊所
- 其他的
根据最终用户，北美子宫癌诊断市场分为医院、诊断中心、癌症研究中心、门诊手术中心、专科诊所和其他。
按分销渠道
- 直接招标
- 第三方分销商
- 其他的
根据分销渠道，北美子宫癌诊断市场分为直接招标、第三方分销商和其他。
北美子宫癌诊断市场区域分析/见解
对北美子宫癌诊断市场进行了分析，并提供了市场规模信息、诊断类型、类型、年龄组、最终用户和分销渠道。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于美国拥有国内生产总值 (GDP) 较高的最大消费市场中的关键市场参与者，并且拥有最新的先进癌症诊断技术和子宫癌诊断发明，预计美国将主导北美子宫癌诊断市场。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。
竞争格局和北美子宫癌诊断市场份额分析
北美子宫癌诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对北美子宫癌诊断市场的关注有关。
北美子宫癌诊断市场的一些主要参与者包括 F-Hoffmann La Roche Ltd.、Siemens Healthcare Private Limited、Narang Medical Limited、ESAOTE SPA、Olympus Corporation、Arquer Diagnostics Ltd、Guzip Biomarkers Corporation、General Electric、Canon Medical Systems ANZ Pty Limited.、KARL STORZ、Medtronic、Stryker、Surtex Instruments Limited.、Koninklijke Philips NV、FUJIFILM Corporation、AED、Jalal Surgical、Integra LifeSciences、B. Braun Melsungen AG 和 GRAIL 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 INSTRUMENT BASED LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PATENT ANALYSIS OF NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET
4.4 REIMBURSEMENT SCENARIO
4.5 INDUSTRY INSIGHTS:
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.7 PRICING STRATEGIES
4.8 CONCLUSION
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER
4.1 COST OF UTERINE CANCER PROCEDURE
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER
6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH
6.2 RESTRAINTS
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER
6.3 OPPORTUNITIES
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS
6.4 CHALLENGES
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE
6.4.2 HIGH COST OF IMAGING SYSTEMS
7 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
7.1 OVERVIEW
7.2 INSTRUMENT-BASED
7.2.1 ULTRASOUND SCANNING
7.2.1.1 SYSTEMS
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING
7.2.1.4 ACCESSORIES
7.2.2 IMAGING DEVICES
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI)
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN
7.2.2.4 OTHERS
7.2.3 TESTS
7.2.3.1 BLOOD TESTS
7.2.3.1.1 COMPLETE BLOOD COUNT
7.2.3.1.2 CA125 MARKER BLOOD TEST
7.2.3.2 URINE TESTS
7.2.3.3 OTHER TESTS
7.2.4 OTHERS
7.3 PROCEDURE BASED
7.3.1 ENDOMETRIAL BIOPSY
7.3.2 HYSTEROSCOPY
7.3.3 DILATION & CURETTAGE
7.3.4 CYSTOSCOPY
7.3.5 PROCTOSCOPY
7.3.6 OTHERS
8 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE
8.1 OVERVIEW
8.2 ENDOMETRIAL CANCER
8.2.1 SEROUS ADENOCARCINOMA
8.2.1.1 INSTRUMENT-BASED
8.2.1.1.1 ULTRASOUND SCANNING
8.2.1.1.2 IMAGING DEVICES
8.2.1.1.3 TESTS
8.2.1.1.4 OTHERS
8.2.1.2 PROCEDURE-BASED
8.2.1.2.1 ENDOMETRIAL BIOPSY
8.2.1.2.2 HYSTEROSCOPY
8.2.1.2.3 DILATION & CURETTAGE
8.2.1.2.4 CYSTOSCOPY
8.2.1.2.5 PROCTOSCOPY
8.2.1.2.6 OTHERS
8.2.2 ADENOSQUAMOUS CARCINOMA
8.2.2.1 INSTRUMENT-BASED
8.2.2.1.1 ULTRASOUND SCANNING
8.2.2.1.2 IMAGING DEVICES
8.2.2.1.3 TESTS
8.2.2.1.4 OTHERS
8.2.2.2 PROCEDURE-BASED
8.2.2.2.1 ENDOMETRIAL BIOPSY
8.2.2.2.2 HYSTEROSCOPY
8.2.2.2.3 DILATION & CURETTAGE
8.2.2.2.4 CYSTOSCOPY
8.2.2.2.5 PROCTOSCOPY
8.2.2.2.6 OTHERS
8.2.3 UTERINE CARCINOSARCOMA
8.2.3.1 INSTRUMENT-BASED
8.2.3.1.1 ULTRASOUND SCANNING
8.2.3.1.2 IMAGING DEVICES
8.2.3.1.3 TESTS
8.2.3.1.4 OTHERS
8.2.3.2 PROCEDURE-BASED
8.2.3.2.1 ENDOMETRIAL BIOPSY
8.2.3.2.2 HYSTEROSCOPY
8.2.3.2.3 DILATION & CURETTAGE
8.2.3.2.4 CYSTOSCOPY
8.2.3.2.5 PROCTOSCOPY
8.2.3.2.6 OTHERS
8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM
8.2.4.1 INSTRUMENT-BASED
8.2.4.1.1 ULTRASOUND SCANNING
8.2.4.1.2 IMAGING DEVICES
8.2.4.1.3 TESTS
8.2.4.1.4 OTHERS
8.2.4.2 PROCEDURE-BASED
8.2.4.2.1 ENDOMETRIAL BIOPSY
8.2.4.2.2 HYSTEROSCOPY
8.2.4.2.3 DILATION & CURETTAGE
8.2.4.2.4 CYSTOSCOPY
8.2.4.2.5 PROCTOSCOPY
8.2.4.2.6 OTHERS
8.3 UTERINE SARCOMA
8.3.1 LEIOMYOSARCOMA
8.3.1.1 INSTRUMENT-BASED
8.3.1.1.1 ULTRASOUND SCANNING
8.3.1.1.2 IMAGING DEVICES
8.3.1.1.3 TESTS
8.3.1.1.4 OTHERS
8.3.1.2 PROCEDURE-BASED
8.3.1.2.1 ENDOMETRIAL BIOPSY
8.3.1.2.2 HYSTEROSCOPY
8.3.1.2.3 DILATION & CURETTAGE
8.3.1.2.4 CYSTOSCOPY
8.3.1.2.5 PROCTOSCOPY
8.3.1.2.6 OTHERS
8.3.2 ENDOMETRIAL STROMAL SARCOMA
8.3.2.1 INSTRUMENT-BASED
8.3.2.1.1 ULTRASOUND SCANNING
8.3.2.1.2 IMAGING DEVICES
8.3.2.1.3 TESTS
8.3.2.1.4 OTHERS
8.3.2.2 PROCEDURE-BASED
8.3.2.2.1 ENDOMETRIAL BIOPSY
8.3.2.2.2 HYSTEROSCOPY
8.3.2.2.3 DILATION & CURETTAGE
8.3.2.2.4 CYSTOSCOPY
8.3.2.2.5 PROCTOSCOPY
8.3.2.2.6 OTHERS
8.3.3 UNDIFFERENTIATED SARCOMA
8.3.3.1 INSTRUMENT-BASED
8.3.3.1.1 ULTRASOUND SCANNING
8.3.3.1.2 IMAGING DEVICES
8.3.3.1.3 TESTS
8.3.3.1.4 OTHERS
8.3.3.2 PROCEDURE-BASED
8.3.3.2.1 ENDOMETRIAL BIOPSY
8.3.3.2.2 HYSTEROSCOPY
8.3.3.2.3 DILATION & CURETTAGE
8.3.3.2.4 CYSTOSCOPY
8.3.3.2.5 PROCTOSCOPY
8.3.3.2.6 OTHERS
9 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 >60 YEARS
9.3 51-60 YEARS
9.4 41-50 YEARS
9.5 31-40 YEARS
9.6 <30 YEARS
10 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 DIAGNOSTIC CENTERS
10.4 CANCER RESEARCH CENTERS
10.5 AMBULATORY SURGICAL CENTERS
10.6 SPECIALIZED CLINICS
10.7 OTHERS
11 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 THIRD PARTY DISTRIBUTORS
11.4 OTHERS
12 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 KONINKLIJKE PHILIPS N.V.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 GENERAL ELECTRIC COMPANY
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 SIEMENS HEALTHCARE GMBH
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 FUJIFILM CORPORATION
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 AED.MD
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 ARQUER DIAGNOSTICS LTD
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 B. BRAUN SE
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ESAOTE SPA
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 GRAIL
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 GUZIP BIOMARKERS CORPORATION
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 INTEGRA LIFESCIENCES
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 JALAL SURGICAL
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 KARL STORZ SE & CO. KG
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
15.16 MEDTRONIC
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENTS
15.17 NARANG MEDICAL LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.18 OLYMPUS CORPORATION
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 STRYKER
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
15.2 SURTEX INSTRUMENTS LIMITED.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA RATE OF ENDOMETRIAL CANCER (2020)
TABLE 2 U.S. (2022)
TABLE 3 U.K. (2019)
TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019)
TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020)
TABLE 6 SINGAPORE (2020)
TABLE 7 JAPAN (2022)
TABLE 8 INDIA (2020)
TABLE 9 AUSTRALIA (2022)
TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018)
TABLE 11 ARGENTINA (2020)
TABLE 12 UAE (2020)
TABLE 13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 18 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 20 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 22 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 27 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 75 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 76 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 78 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 79 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 81 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 82 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 83 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 84 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 85 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 86 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 87 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 88 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 89 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 90 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 91 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 92 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 93 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 94 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 95 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 96 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 97 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 98 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 99 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 100 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 101 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 103 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 104 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 105 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 106 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 107 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 108 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 109 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 110 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 111 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 112 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 113 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 115 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 118 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 119 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 120 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 121 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 122 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 123 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 124 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 125 U.S. TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 126 U.S. BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 127 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 128 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 129 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 130 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 132 U.S. SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 133 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 134 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 135 U.S. ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 136 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 137 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 138 U.S. UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 139 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 140 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 141 U.S. PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 142 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 143 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 144 U.S. UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 U.S. LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 146 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 147 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 148 U.S. ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 149 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 150 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 151 U.S. UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 152 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 153 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 154 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 155 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 156 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 157 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 158 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 159 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 160 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 161 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 162 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 163 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 164 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 165 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 166 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 167 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 168 CANADA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 169 CANADA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 170 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 171 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 172 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 173 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 174 CANADA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 CANADA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 176 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 177 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 178 CANADA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 179 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 180 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 181 CANADA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 182 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 183 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 184 CANADA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 185 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 186 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 187 CANADA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 188 CANADA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 189 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 190 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 191 CANADA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 192 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 193 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 194 CANADA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 195 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 196 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 197 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 198 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 199 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 200 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 201 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 202 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 203 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 204 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 205 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 206 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 207 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 208 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 209 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 210 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 211 MEXICO TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 212 MEXICO BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 213 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 214 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 215 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 216 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 217 MEXICO ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 218 MEXICO SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 219 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 220 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 221 MEXICO ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 222 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 223 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 224 MEXICO UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 225 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 226 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 227 MEXICO PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 228 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 229 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 230 MEXICO UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 231 MEXICO LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 232 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 233 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 234 MEXICO ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 235 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 236 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 237 MEXICO UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 238 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 239 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 240 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 241 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF UTERINE CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 INSTRUMENT BASED SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE UTERINE CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2022
FIGURE 15 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2022
FIGURE 19 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 23 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 27 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030)
FIGURE 39 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
